R&D Spending Showdown: Alpine Immune Sciences, Inc. vs Ligand Pharmaceuticals Incorporated

Biotech R&D: Alpine's Aggressive Growth vs. Ligand's Stability

__timestampAlpine Immune Sciences, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 20141219954712122000
Thursday, January 1, 20151605400013380000
Friday, January 1, 20162331600021221000
Sunday, January 1, 20171062600026887000
Monday, January 1, 20182897000027863000
Tuesday, January 1, 20193584700055908000
Wednesday, January 1, 20202718500059392000
Friday, January 1, 20215874200069012000
Saturday, January 1, 20227024300036082000
Sunday, January 1, 20238090400024537000
Loading chart...

In pursuit of knowledge

R&D Spending Trends: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and Ligand Pharmaceuticals Incorporated have been at the forefront of this race. From 2014 to 2023, Alpine Immune Sciences has shown a remarkable increase in R&D expenses, growing by over 560%, peaking in 2023. In contrast, Ligand Pharmaceuticals saw a more modest increase of around 100% during the same period, with a peak in 2021. This divergence highlights Alpine's aggressive push towards innovation, while Ligand's spending reflects a more stable approach. The data suggests that Alpine's strategy may be paying off, as their R&D spending surpassed Ligand's by 2023. This trend underscores the dynamic nature of the biotech industry, where strategic investments in R&D can drive future growth and success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025